Global Federated RWE Networks

Every element this module has built — RWD sources, study designs, confounding control, OMOP standardisation — comes together operationally in the federated networks actually running RWE studies at scale today. The core architectural insight behind every network in this lesson’s comparison table is genuinely elegant: rather than centralising raw patient data from multiple countries into one location (which would run headlong into exactly the kind of national data protection restrictions Module 11 touched on for PSMF compliance), each participating database applies pre-specified analytical code locally, produces aggregate, non-patient-identifiable results, and shares only those results with the study’s coordinating centre. Patient-level data never leaves the jurisdiction of the organisation that holds it.

This resolves what would otherwise be a genuine, structural tension in international pharmacovigilance: detecting rare signals reliably requires large, diverse, cross-national populations — exactly the kind of scale a single country’s data often can’t provide on its own — while national and regional data protection laws (GDPR in the EU, India’s DPDP Act, HIPAA in the US) genuinely restrict cross-border transfer of identifiable patient data. Federation lets the field have both: population-scale analytical power, without centralising anything that would violate any individual jurisdiction’s data protection requirements.

FDA’s Sentinel system, now scaling through its Sentinel NextGen iteration, runs active surveillance across US health insurance claims and EHR data covering over 100 million lives, with AI-enhanced signal analytics and near-real-time monitoring for selected product classes — this is the infrastructure Module 14’s Vaccine Safety Datalink lesson previewed directly. EMA’s DARWIN EU, operational since 2022, mandates OMOP CDM for every participating database and runs regulatory RWE studies specifically commissioned by EMA for PRAC signal evaluation — and, as this lesson’s update callout notes, its first regulatory-grade PRAC signal assessment studies actually completed in 2025-26, a genuine milestone. The WHO-UMC AI Hub extends this federated model globally, running federated NLP and signal detection algorithms at each national site — including smaller national databases where rare-disease signals would otherwise be nearly undetectable in isolation — with only aggregate results shared centrally.

Japan’s MID-NET, built on ten large hospital information systems, supports Japan-specific post-marketing surveillance studies, particularly for hepatotoxicity, QT prolongation, and other rare ADR investigations. Canada’s CNODES runs a distributed analysis network across seven provinces’ administrative health databases for comparative safety studies. And India’s CDSCO National RWE Hub, in pilot phase as of 2025-26, is a genuinely significant development for this course’s audience specifically: it’s the first infrastructure connecting hospital EHR data from tertiary care centres directly with PvPI’s spontaneous ICSR database, enabling — for the first time — proper incidence estimation and signal validation specifically for Indian patient populations, with explicit priority given to elderly, paediatric, pregnant, and traditional-medicine-using populations that have historically been underrepresented in global RWD infrastructure.